Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2158)	7/30/2017 3:16:13 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

One small clarification from Bayer 2Q Eylea sale....smaller than expected growth in Eylea sale (11% versus 15-20%) was due to headwind (~20m rebate in Germany, and order pattern in Japan). I do believe that Eylea WW sale will continue to increase by at lest 15% y/y for next +2 year (until they reach e700 M/Q or close what is today in US per Q). In addition to tonight Sanofi 2Q report, I think that next week is important to REGN. Is Dupilumab currently just hype, or it is real thing for next 2-3 years and beyond??? Finger crossed!